881673-68-3

Usage

Molecular structure

The molecule is an ethyl ester derivative of 1H-pyrrole-3-carboxylic acid with a chloro substitution at the 2-position and a trifluoromethylphenyl group at the 5-position.

Usage in pharmaceutical industry

It is commonly used as a building block for the synthesis of various pharmaceuticals and biologically active molecules.

Biological activity

It has been studied for its potential antibacterial, antifungal, and antiviral properties.

Trifluoromethyl substituent

Known for its ability to enhance the biological activity and metabolic stability of drug molecules.

Importance in medicinal chemistry

It is an important intermediate in medicinal and pharmaceutical chemistry due to its biological activity and trifluoromethyl substituent.

Upstream product

• 54109-16-9 2-(trifluoromethyl)phenacyl bromide 
• 105-56-6 ethyl 2-cyanoacetate 
• 17408-14-9 1-(2-(trifluoromethyl)phenyl)ethan-1-one 
• 881673-53-6 ethyl 2-cyano-4-oxo-4-[2-(trifluoromethyl)phenyl]butanoate 

Downstream Products

• 881673-54-7 ethyl 5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate 
• 881674-62-0 C₁₂H₁₀F₃NO 
• 881674-60-8 5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbaldehyde 
• 881677-15-2 1-(pyridin-3-ylsulfonyl)-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbaldehyde 
• 881673-67-2 1-[(4-methylphenyl)sulfonyl]-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbaldehyde 
• 881678-65-5 N-methyl-1-{{1-(4-methylphenyl)sulfonyl}-5-[2-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methanamine hydrochloride 

Relevant academic research and scientific papers

Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action

With the aim to find a novel long-lasting potassium-competitive acid blocker (P-CAB) that would perfectly overcome the limitations of proton pump inhibitors (PPIs), we tried various approaches based on pyrrole derivative 1b as a lead compound. As part of

Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3- ylsulfonyl)-1 H -pyrrol-3-yl]- n -methylmethanamine fumarate (tak-438) as a Potassium-Competitive Acid Blocker (P-CAB)

In our pursuit of developing a novel and potent potassium-competitive acid blocker (P-CAB), we synthesized pyrrole derivatives focusing on compounds with low log"‰D and high ligand-lipophilicity efficiency (LLE) values. Among the compounds synthesized, the compound 13e exhibited potent H +,K+-ATPase inhibitory activity and potent gastric acid secretion inhibitory action in vivo. Its maximum efficacy was more potent and its duration of action was much longer than those of proton pump inhibitors (PPIs). Therefore, compound 13e (1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)- 1H-pyrrol-3-yl]-N-methylmethanamine fumarate, TAK-438) was selected as a drug candidate for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer, and other acid-related diseases.

Acid secretion inhibitor

The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R2 is an optionally substituted C6-14 aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, R3 and R4 are each a hydrogen atom, or one of R3 and R4 is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R5 is an alkyl group or a salt thereof.